CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 36 target
Drug / intervention
Surufatinib +2 moredrug
Likely dose
Surufatinib 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05472948
NCT05472948Phase 2RecruitingOn TrackUpdated 6mo ago
Long Recruiting
CompareCT.gov

Surufatinib and Sintilimab in Combination With Capecitabine for Previously Treated Metastatic Small Bowel Adenocarcinoma and Appendiceal Carcinoma: A Single-arm, Multi-center, Phase Ib/II Trial

Sun Yat-sen University·interventional·Posted Jul 25, 2022·Updated Dec 17, 2025

In Brief

A Phase 2 clinical trial evaluating Surufatinib, Sintilimab, and 1 other intervention for Adenocarcinoma of Small Intestine and 2 related conditions. Currently recruiting, targeting 36 participants across 1 site.

Detailed Summary

To explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial. Meanwhile, Exploring the maximum tolerant dose or recommended II research dose of Surufatinib combined with a fixed dose of Sintilimab and Capecitabine using 3 + 3 dose climbing experiment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
202320242025202620272028
First PostedJul 25, 2022
Enrollment StartFeb 1, 2023
Primary CompletionDec 30, 2027
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 3.9 years agoPrimary completion in 1.5 years

Interventions

Surufatinibdrug

Surufatinib will be given 200/250 mg po. qd.

Sintilimabdrug

Sintilimab administered IV at a dose of 200mg every 3 weeks.

Capecitabinedrug

Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)